Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | JAK2 R683G |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK2 Inhibitor JAK2 Inhibitor - ATP competitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 R683G JAK2 E864K | cancer | resistant | NVP-BSK805 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575). | 22271575 |
JAK2 R683G JAK2 E864K | cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |
JAK2 R683G JAK2 G935R | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575). | 22271575 |
JAK2 R683G JAK2 G935R | cancer | resistant | NVP-BSK805 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575). | 22271575 |
JAK2 R683G JAK2 G935R | cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |